Published Date: 01 Mar 2023
Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing problems or obstruction in urination...
Read Full NewsBacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.
Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood. New research now highlights a molecular chain of events in estrogen receptor-positive breast cancer, ...
Long-term breast cancer survivors have a higher risk for developing depression, particularly if they have insomnia, according to a study published online Oct. 10 in SLEEPJ.
Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe that resists the breakdown of certain compounds in the body, giving doctors a more dependable way ...
1.
Some triple negative breast cancers might be avoided by longer breastfeeding
2.
The Effect of Common Steroids on Cancer Treatments.
3.
Gene therapies for BCG-unresponsive bladder cancer have high response rates.
4.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
5.
Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?
1.
Exploring the Latest Treatments for Desmoid Tumors
2.
The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment
3.
The Pros and Cons of Using Cyclophosphamide in Cancer Treatment
4.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
5.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
3.
Updates on the First Line Management of ALK+ NSCLC
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
5.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation